DIABETIC GASTROPARESIS TREATMENT MARKET ANALYSIS

The Global Diabetic Gastroparesis Treatment Market is estimated to be valued at US$  2,271.7 million in 2023 and is expected to exhibit a CAGR of 3.6 % during the forecast period (2023-2030).

Analysts’ Views on Global Diabetic Gastroparesis Treatment Market:

Increasing number of geriatric population, increasing prevalence of diabetes and easy availability of over-the-counter medications are expected to boost the growth of global diabetic gastroparesis treatment market within the forecast period. For instance, according to an article updated by National Center for Biotechnology Information in March 2022, upper gastrointestinal symptoms are reported in 11% to 18% of patients with diabetes, out of which most of them are associated with delayed gastric emptying or gastroparesis. Gastroparesis is seen in approximately 4.8% of individuals with type 1 diabetes, 1% of those with type 2 diabetes, and 0.1% of those without diabetes. Although, there is a stronger association between type 1 diabetes and gastroparesis, the incidence of gastroparesis is much higher in type 2 diabetes patients, and therefore, gastroparesis associated with type 2 diabetes is seen more frequently.

Figure 1. Global Diabetic Gastroparesis Treatment Market Share (%), by Product Type, 2023

To learn more about this report, request sample copy

Global Diabetic Gastroparesis Treatment Market – Driver

Increasing Prevalence of Diabetes Worldwide

The growing diabetes mellitus population worldwide is a major factor leading to the high demand for diabetic gastroparesis drugs. For instance, according to the data published by International Diabetes Federation in September 2021, it is estimated that approximately 537 million adults will be living with diabetes in 2021, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. It is also estimated that 3 in 4 adults with diabetes will live in low- and middle-income countries in 2021. Furthermore, according to an article published by Frontiers journal in March 2022, a study in India showed that the prevalence of diabetes mellitus in India was 9.3%. Among those with diabetes mellitus, 45.8% were aware, 36.1% were on treatment, and 15.7% had it under control. Hence, with the increasing prevalence of diabetes, diabetic gastroparesis is also expected to increase, thus enhancing growth of global diabetic gastroparesis market .

/p>

Increasing geriatric population across world

The increasing geriatric population across the world is expected to drive growth of global diabetic gastroparesis market. The diabetes is commonly seen disorder in old aged people. For instance, according to data published on World Population Prospects 2022 by United Nations Department of Economics and Social Affairs, the share of the global population aged 65 years or above is projected to rise from 10 per cent in 2022 to 16 percent in 2050. Also, globally, women outnumber men at older ages. In 2022, women comprised 55.7 per cent of persons aged 65 or older.

Figure 2. Global Diabetic Gastroparesis Treatment Market Value (US$ Million), by Region, 2023

To learn more about this report, request sample copy

Global Diabetic Gastroparesis Treatment Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global diabetic gastroparesis treatment market over the forecast period. This is due to the increasing aging population and the rising number of surgical procedures. The U.S. dominated the market owing to a large prediabetic population, favorable reimbursement policies, and more awareness about the condition. For instance, according to the data from Centers for Drug Control and Prevention in June 2022, 96 million people aged 18 years or older have prediabetes (38.0% of the adult U.S. population). Furthermore, increasing healthcare expenditure, a growing number of hospitals, and the presence of well-established healthcare infrastructure are also responsible for the dominance of the region in the market. Thus, the rise in diabetes cases is anticipated to increase market growth over the forecast period.

Global Diabetic Gastroparesis Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global diabetic gastroparesis treatment market. This is because of reduced patients visit to hospitals during COVID-19 period.  For instance, according to data shared by the Commonwealth Fund on May 19, 2020, the number of visits of patients to hospitals were declined nearly 60%. Even when rebound occurred, number of visits were still roughly one third lower than what was seen before the pandemic.

Global Diabetic Gastroparesis Treatment Market Segmentation:

The Global Diabetic Gastroparesis Treatment Market report is segmented into by Product Type, by Disease Indication, by Distribution channel, and Region.

By Product Type, the market is segmented into Drugs and Surgical treatments. Out of which, the drug segment is expected to hold a dominant position in the Global Diabetic Gastroparesis Treatment  market during the forecast period and this is attributed to increasing number of antiemetic medication as OTC products.

By Disease Indication, the market is segmented into Compensated Gastroparesis, Gastric Failure.  Out of which, the Compensated Gastroparesis segment is expected to hold a dominant position in the Diabetic Gastroparesis Treatment market during the forecast period and this is attributed to the increasing awareness and healthcare facilities, that very less number of cases are advanced to Gastric failure condition.

By Distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Out of which, the Hospital Pharmacies segment is expected to dominate the market over the forecast period and this is attributed to the increasing number of hospital pharmacies.

Among all the segmentations, the product type segment has the highest potential due to the increasing research and development activities across world over the forecast period. For instance, in December 2022, Evoke Pharma, Inc., a U.S. based pharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) issued a U.S. patent No. 11,517,545 under the title “Treatment of Moderate and Severe Gastroparesis’’ which covers the usage of Gimoti (metoclopramide). Gimoti is a nasal spray used to treat diabetic gastroparesis, a complication of diabetes where the stomach's digestion  slows down. Canadian Intellectual Property Office granted the company a key patent for its previously submitted application (CA 2984736). The received patent is for Gimoti’s method of use.

Global Diabetic Gastroparesis Treatment Market Cross Sectional Analysis:

Among distribution channel, retail pharmacies held as a dominant segment in Asia Pacific region due to rising launches of retail pharmacies in India . For instance, in April 2023, Davaindia Generic Pharmacy, the largest private generic pharmacy retail network and a trademark of Zota Healthcare Ltd, recently launched its 100th Company Owned and Company Operated (COCO) store. The 100th store was launched in the Gulbarga district of Karnataka, India.

Global Diabetic Gastroparesis Treatment Market : Key Developments

For instance, in July 2020, the U.S. Food and Drug Administration (FDA) approved the use of tradipitant, a product of Vanda Pharmaceuticals, a U.S.-based biopharmaceutical company, for up to 6 months with an option of renewal for an individual patient who requested expanded access of drug for the treatment of gastroparesis

In July 15, 2020, Evoke Pharma, U.S. based pharmaceutical company Initiated Commercial Manufacturing of Gimoti after it got U.S. Food and Drug Administration approval for the same in June 2020. Gimoti is a nasal spray used to treat diabetic gastroparesis, a complication of diabetes where the stomach's digestion  slows down. The company along with Patheon, a U.S.-based commercial manufacturing company has started manufacturing process and planned to launch the product by fourth quarter of 2020.

In March, 2021, Johns Hopkins Medicine conducted a clinical trial on Gastric per-oral Endoscopic Myotomy for the treatment of for the management of refractory gastroparesis . The G-POEM procedure was determined to be safe, although its overall efficacy in treating refractory gastroparesis was moderate.

In April 9, 2022, according to study published in Iranian Journal of Basic Medical Sciences, Atractylodes chinensis volatile oil can be used to treat diabetic gastroparesis. The animal study was carried out where Atractylodes chinensis volatile oil effectively promoted gastric emptying and intestinal propulsion in the diabetic gastroparesis rats and increased gastric acid secretion. Furthermore, after the treatment of Atractylodes chinensis volatile oil, the serum insulin like growth factor-1 level in diabetic gastroparesis rats was increased. The morphology and arrangement of the cells and the number of interstitial cell of cajal in the gastric tissue were restored. Hence it was concluded that Atractylodes chinensis volatile oil  plays a positive role in the treatment of diabetic gastroparesis.

Global Diabetic Gastroparesis Treatment Market : Key Trends

Research and development activities across the world can drive the growth of Diabetic Gastroparesis Treatment market within the forecast period. For instance, according to article published in Journal Europe PMC on July 29, 2022, Chinese herbal medicine Zhi Shi Xiao Pi Wan has an effect on adult diabetic gastroparesis with lesser side effects.

In December 14, 2022, a clinical trial by Mayo clinic, a U.S. based academic medical center was initiated  on use of Rifaximin  for treatment of diabetic gastroparesis.

Global Diabetic Gastroparesis Treatment Market : Restraint

Termination of clinical trials

Withdrawal/termination of clinical trials is also expected to hamper growth of the market. There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is due to early termination of clinical trials or failure of drugs to meet statistically significant endpoints. For instance, in October 23, 2020, clinical trials on use of Docusate/ Senna for treatment of Diabetic Gastroparesis was terminated due to lack of recruitment.

Lack of awareness about the disease

Diabetic gastroparesis is a significant gastrointestinal condition. However, a substantial population is unaware or have very less information regarding the symptoms, possible treatments of the disease. According to study published in Journal of Neurogastroenterology and Motility on October 17, 2020, a survey was conducted with total 490 doctors across Asia. It was found that only 41.7% respondents had access to gastric emptying scintigraphy. Most of doctors had never diagnosed gastroparesis at all or diagnosed fewer than 5 patients a year due to lack of awareness amongst people.

Global Diabetic Gastroparesis Treatment Market - Key Players

Major players operating in the Global Diabetic Gastroparesis Treatment Market include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.

*Definition: Diabetic gastroparesis is delayed gastric emptying associated with diabetes. The condition occurs in patients suffering from both type-1 and type- 2 diabetes and is more common in female patients suffering from type-2 diabetes. The disease involves delayed emptying of the stomach leading to a series of symptoms such as nausea, vomiting, abdominal bloating, abdominal pain, weight loss, gastroesophageal reflux, spasms of the stomach wall, and heartburn.